Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

Schlenk, RF; Weber, D; Fiedler, W; Salih, HR; Wulf, G; Salwender, H; Schroeder, T; Kindler, T; Lübbert, M; Wolf, D; Westermann, J; Kraemer, D; Götze, KS; Horst, HA; Krauter, J; Girschikofsky, M; Ringhoffer, M; Südhoff, T; Held, G; Derigs, HG; Schroers, R; Greil, R; Grießhammer, M; Lange, E; Burchardt, A; Martens, U; Hertenstein, B; Marretta, L; Heuser, M; Thol, F; Gaidzik, VI; Herr, W; Krzykalla, J; Benner, A; Döhner, K; Ganser, A; Paschka, P; Döhner, H.

Blood. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453. Epub 2018 Dec 18.

https://pubmed.ncbi.nlm.nih.gov/30563875/